ME1 — Melodiol Global Health Share Price
0.000.00%
Last trade - 00:00- AU$0.02m
- AU$8.98m
- AU$19.60m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | -389.56% | ||
| Operating Margin | -136.63% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 3.68 | 2.45 | 6.22 | 6.32 | 19.6 | n/a | n/a | 94.6% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Melodiol Global Health Limited is an Australia-based cannabis company. The Company develops cannabis, hemp-derived and other plant-based therapeutic, nutraceutical, and lifestyle products. The Company distributes pharmaceuticals internationally, specializing in the distribution of medicinal cannabis products across Australasia, and non-cannabis products in the United Kingdom and Europe. It also develops and sells beauty and personal care products, produced using plant-based processes, including under the brands Green Goo, Southern Butter and Good Goo. Its segments include Europe, Canada and Asia Pacific. Its Europe segment includes Health House International Limited (HHI), UK division, which distributes pharmaceutical products, and Creso Pharma Switzerland GmbH, which includes the development and commercialization of its nutraceutical products located in Switzerland. Its Canada segment includes Mernova Medicinal Inc, a producer of cannabis products and sells under the Ritual brand.
Directors
- Adam Blumenthal NEC
- William Lay CEO
- David Russell COO
- Michal Masek MDR
- Roman Strechaj MDR
- James Ellingford EDR
- Micheline Mackay EDR
- Miriam Wernli EDR
- Erlyn Dale SEC
- Winton Willesee SEC
- Bruce Linton NED (55)
- Boaz Wachtel NED
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- November 20th, 2015
- Public Since
- October 20th, 2016
- No. of Shareholders
- 26,431
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Australian Stock Exchange - SEATS
- Shares in Issue
- 7,903,088.55
- Address
- Suite 5 CPC, PERTH, 6009
- Web
- https://www.cresopharma.com/
- Phone
- +61 280678606
- Auditors
- Crowe ?Audit Australia
Upcoming Events for ME1
Similar to ME1
Acrux
Australian Stock Exchange - SEATS
AFT Pharmaceuticals
Australian Stock Exchange - SEATS
Althea group
Australian Stock Exchange - SEATS
Anatara Lifesciences
Australian Stock Exchange - SEATS
Argent BioPharma
Australian Stock Exchange - SEATS
FAQ
What is the Melodiol Global Health share price?
As of Today at 16:02 UTC, shares in Melodiol Global Health are trading at AU$0.01. This share price information is delayed by 15 minutes.
How has the Melodiol Global Health share price performed this year?
Shares in Melodiol Global Health last closed at AU$0.01 and the price had moved by -95% over the past 365 days. In terms of relative price strength the Melodiol Global Health share price has underperformed the ASX All Ordinaries Index by -95.45% over the past year.
What are the analyst and broker recommendations for Melodiol Global Health?
There is no consensus recommendation for this security.
What is the Melodiol Global Health dividend yield?
Melodiol Global Health does not currently pay a dividend.
Does Melodiol Global Health pay a dividend?
Melodiol Global Health does not currently pay a dividend.
When does Melodiol Global Health next pay dividends?
Melodiol Global Health does not currently pay a dividend.
How do I buy Melodiol Global Health shares?
To buy shares in Melodiol Global Health you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Melodiol Global Health?
As of the previous close price of AU$0.01, shares in Melodiol Global Health had a market capitalisation of AU$0.06m.
Where are Melodiol Global Health shares listed?
Here are the trading details for Melodiol Global Health:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: ME1
What kind of share is Melodiol Global Health?
Based on an overall assessment of its quality, value and momentum Melodiol Global Health is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Melodiol Global Health share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Melodiol Global Health share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Melodiol Global Health. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -65.78%.
As of the last closing price of AU$0.01, shares in Melodiol Global Health were trading -82.3% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Melodiol Global Health PE Ratio?
The Melodiol Global Health PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.01.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Melodiol Global Health?
Melodiol Global Health's management team is headed by:
- Adam Blumenthal - NEC
- William Lay - CEO
- David Russell - COO
- Michal Masek - MDR
- Roman Strechaj - MDR
- James Ellingford - EDR
- Micheline Mackay - EDR
- Miriam Wernli - EDR
- Erlyn Dale - SEC
- Winton Willesee - SEC
- Bruce Linton - NED
- Boaz Wachtel - NED